Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 144 weeks of public selections as part of this ongoing live forward-testing. In...
Curaleaf (CURA CN) initiated with Neutral rating and C$11.40 (41% upside) price target at Cantor Fitzgerald. U.S. ticker: ( OTCPK:CURLF ). More news on: Curaleaf Holdings, Inc., Pfenex Inc., Trulieve Cannabis Corp., Healthcare stocks news, Stocks on the move, , Read more ...
Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without the right implementation can do more harm than good. This is especially true among growth stocks because the...
Gainers: CHS +26.9% . DBVT +21.6% . AGTC +13.9% . NNVC +10.3% . OTCQX:AKOM +9.1% . More news on: Chico's FAS, Inc., DBV Technologies S.A., Applied Genetic Technologies Corporation, Stocks on the move, , News on ETFs Read more ...
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for Pneumosil, a 10-valent pneumococcal conjugate vaccine. Pneumosil conta...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 138 weeks of public selections as part of this ongoing live forward-testing. In...
The company Pfenex ( PFNX ) is a 'development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology to develop and improve protein therapies for unmet patient needs.' The company has made great progress since my first article, entitled ' Pfenex: A Buy...
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities fo...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on multiple discriminant analysis ((MDA)) breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 135 weeks of public selections as part of t...
SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...